共 33 条
- [31] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialLANCET ONCOLOGY, 2016, 17 (04): : 425 - 439Cristofanilli, MassimoTurner, Nicholas C.Bondarenko, IgorRo, JungsilIm, Seock-AhMasuda, NorikazuColleoni, MarcoDeMichele, AngelaLoi, ShereneVerma, SunilIwata, HirojiHarbeck, NadiaZhang, KeTheall, Kathy PuyanaJiang, YuqiuBartlett, Cynthia HuangKoehler, MariaSlamon, Dennis
- [32] Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2023, 24 (06): : 646 - 657Zhang, PinZhang, QingyuanTong, ZhongshengSun, TaoLi, WeiOuyang, QuchangHu, XichunCheng, YingYan, MinPan, YueyinTeng, YueeYan, XiWang, YingXie, WeiminZeng, XiaohuaWang, XiaojiaHu, ChangluGeng, CuizhiZhang, HongweiLi, WenxinWu, XinhongZhong, JincaiXu, JingweiShi, YanxiaWei, WenhuaBayaxi, NayimaZhu, XiaoyuXu, Binghe
- [33] Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialLANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (08): : 705 - 717Kang, Yoon-KooTerashima, MasanoriKim, Young-WooBoku, NarikazuChung, Hyun CheolChen, Jen-ShiJi, JiafuYeh, Ta-SenChen, Li-TzongRyu, Min-HeeKim, Jong GwangOmori, TakeshiRha, Sun YoungKim, Tae YongRyu, Keun WonSakuramoto, ShinichiNishida, YasunoriFukushima, NorimasaYamada, TakanobuBai, Li-YuanHirashima, YoshinoriHagihara, ShunsukeNakada, TakashiSasako, Mitsuru